FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010403732> ?p ?o ?g. }

• W3010403732 endingPage "608" @default.
• W3010403732 startingPage "608" @default.
• W3010403732 abstract "Tumor resistance to chemotherapy represents an important challenge in modern oncology. Although platinum (Pt)-based drugs have demonstrated excellent therapeutic potential, their effectiveness in a wide range of tumors is limited by the development of resistance mechanisms. One of these mechanisms includes increased cisplatin sequestration/efflux by the copper-transporting ATPase, ATP7B. However, targeting ATP7B to reduce Pt tolerance in tumors could represent a serious risk because suppression of ATP7B might compromise copper homeostasis, as happens in Wilson disease. To circumvent ATP7B-mediated Pt tolerance we employed a high-throughput screen (HTS) of an FDA/EMA-approved drug library to detect safe therapeutic molecules that promote cisplatin toxicity in the IGROV-CP20 ovarian carcinoma cells, whose resistance significantly relies on ATP7B. Using a synthetic lethality approach, we identified and validated three hits (Tranilast, Telmisartan, and Amphotericin B) that reduced cisplatin resistance. All three drugs induced Pt-mediated DNA damage and inhibited either expression or trafficking of ATP7B in a tumor-specific manner. Global transcriptome analyses showed that Tranilast and Amphotericin B affect expression of genes operating in several pathways that confer tolerance to cisplatin. In the case of Tranilast, these comprised key Pt-transporting proteins, including ATOX1, whose suppression affected ability of ATP7B to traffic in response to cisplatin. In summary, our findings reveal Tranilast, Telmisartan, and Amphotericin B as effective drugs that selectively promote cisplatin toxicity in Pt-resistant ovarian cancer cells and underscore the efficiency of HTS strategy for identification of biosafe compounds, which might be rapidly repurposed to overcome resistance of tumors to Pt-based chemotherapy." @default.
• W3010403732 created "2020-03-13" @default.
• W3010403732 creator A5002387034 @default.
• W3010403732 creator A5010400625 @default.
• W3010403732 creator A5018175643 @default.
• W3010403732 creator A5023546203 @default.
• W3010403732 creator A5038044408 @default.
• W3010403732 creator A5041329002 @default.
• W3010403732 creator A5043233325 @default.
• W3010403732 creator A5051885220 @default.
• W3010403732 creator A5056616527 @default.
• W3010403732 creator A5065615846 @default.
• W3010403732 creator A5069509800 @default.
• W3010403732 creator A5074174936 @default.
• W3010403732 creator A5076356293 @default.
• W3010403732 creator A5090295114 @default.
• W3010403732 date "2020-03-06" @default.
• W3010403732 modified "2023-09-24" @default.
• W3010403732 title "Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin" @default.
• W3010403732 cites W1498913998 @default.
• W3010403732 cites W1605765845 @default.
• W3010403732 cites W1772070405 @default.
• W3010403732 cites W1967868572 @default.
• W3010403732 cites W1976760172 @default.
• W3010403732 cites W1981172976 @default.
• W3010403732 cites W1985580136 @default.
• W3010403732 cites W1990729534 @default.
• W3010403732 cites W1991149656 @default.
• W3010403732 cites W1991645115 @default.
• W3010403732 cites W1996294176 @default.
• W3010403732 cites W1999105379 @default.
• W3010403732 cites W2000130246 @default.
• W3010403732 cites W2010269097 @default.
• W3010403732 cites W2028867335 @default.
• W3010403732 cites W2029144698 @default.
• W3010403732 cites W2038955988 @default.
• W3010403732 cites W2042083290 @default.
• W3010403732 cites W2053923285 @default.
• W3010403732 cites W2060606218 @default.
• W3010403732 cites W2062941476 @default.
• W3010403732 cites W2076992552 @default.
• W3010403732 cites W2079351077 @default.
• W3010403732 cites W2080040488 @default.
• W3010403732 cites W2084492467 @default.
• W3010403732 cites W2091223454 @default.
• W3010403732 cites W2092914966 @default.
• W3010403732 cites W2093477805 @default.
• W3010403732 cites W2097334193 @default.
• W3010403732 cites W2107417411 @default.
• W3010403732 cites W2113689159 @default.
• W3010403732 cites W2128222869 @default.
• W3010403732 cites W2136615414 @default.
• W3010403732 cites W2137228719 @default.
• W3010403732 cites W2139840013 @default.
• W3010403732 cites W2141037581 @default.
• W3010403732 cites W2147722908 @default.
• W3010403732 cites W2155418839 @default.
• W3010403732 cites W2162330234 @default.
• W3010403732 cites W2164277862 @default.
• W3010403732 cites W2168236445 @default.
• W3010403732 cites W2419781546 @default.
• W3010403732 cites W2526283448 @default.
• W3010403732 cites W2734515731 @default.
• W3010403732 cites W2768564401 @default.
• W3010403732 cites W2802231193 @default.
• W3010403732 cites W2894960207 @default.
• W3010403732 cites W2900780680 @default.
• W3010403732 doi "https://doi.org/10.3390/cancers12030608" @default.
• W3010403732 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7139527" @default.
• W3010403732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32155756" @default.
• W3010403732 hasPublicationYear "2020" @default.
• W3010403732 type Work @default.
• W3010403732 sameAs 3010403732 @default.
• W3010403732 citedByCount "22" @default.
• W3010403732 countsByYear W30104037322020 @default.
• W3010403732 countsByYear W30104037322021 @default.
• W3010403732 countsByYear W30104037322022 @default.
• W3010403732 countsByYear W30104037322023 @default.
• W3010403732 crossrefType "journal-article" @default.
• W3010403732 hasAuthorship W3010403732A5002387034 @default.
• W3010403732 hasAuthorship W3010403732A5010400625 @default.
• W3010403732 hasAuthorship W3010403732A5018175643 @default.
• W3010403732 hasAuthorship W3010403732A5023546203 @default.
• W3010403732 hasAuthorship W3010403732A5038044408 @default.
• W3010403732 hasAuthorship W3010403732A5041329002 @default.
• W3010403732 hasAuthorship W3010403732A5043233325 @default.
• W3010403732 hasAuthorship W3010403732A5051885220 @default.
• W3010403732 hasAuthorship W3010403732A5056616527 @default.
• W3010403732 hasAuthorship W3010403732A5065615846 @default.
• W3010403732 hasAuthorship W3010403732A5069509800 @default.
• W3010403732 hasAuthorship W3010403732A5074174936 @default.
• W3010403732 hasAuthorship W3010403732A5076356293 @default.
• W3010403732 hasAuthorship W3010403732A5090295114 @default.
• W3010403732 hasBestOaLocation W30104037321 @default.
• W3010403732 hasConcept C104317684 @default.
• W3010403732 hasConcept C114851261 @default.
• W3010403732 hasConcept C126322002 @default.
• W3010403732 hasConcept C133936738 @default.

• next